Clinical Trial Update: Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD [Phase 1]

View source ↗

Summary

Phase 1 trial comparing safety of CGC-11047 given every 2 weeks vs every 4 weeks in patients with CNV due to Age-related macular degeneration; results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• CGC-11047 (PG-11047)

Snippet

Sponsor: Progen Pharmaceuticals | Conditions: Age Related Macular Degeneration | Phase 1 | Status: COMPLETED | Results posted: 2012-08-06